6 Articles found
Adaptive Biotechnologies Articles
-
A Reflection on Blood Cancer Awareness Month: Patient Spotlight
As September and Blood Cancer Awareness Month wrap up, we want to reflect on a memorable conversation with Karen Thomas, a woman who received clonoSEQ® testing, and her physician, Dr. Hazma Hashmi, a hematologist-oncologist from the ...
-
Tackling Barriers to MRD Adoption in the Community Setting
The day a person receives a cancer diagnosis is likely one of the worst days of their lives. For some new patients, the typical approach may be to seek care from a specialist at an NCCN-designated cancer center. But for the majority of ...
-
Clinician Attitudes are Shifting on MRD-guided Decision Making in Multiple Myeloma
This September marks four years since the 2018 Food and Drug Administration clearance for clonoSEQ to detect and monitor minimal residual disease (MRD) in bone marrow from patients with acute lymphoblastic leukemia (ALL) and multiple myeloma ...
-
SPIN Girls Field Day Retrospective
"If it makes sense to you it doesn’t have to make sense to anyone else. Follow your passion." Here at Adaptive we understand that fostering an empowering environment for future STEM leaders through rich mentoring opportunities will be ...
-
Adaptive MRD Chief Commercial Officer Nitin Sood Shares How His Personal Journey Has Shaped His Career Path
Here at Adaptive, putting the patient first is a core value—a philosophy that deeply resonates with me. Similar to many of my fellow Adapters, my inspiration is personal and I’m excited by the tremendous potential impact we can ...
-
Whatever Happens, the Patient Has to be at the Center
In honor of World Cancer Day, we sat down with two Adapters to understand how their personal experiences with cancer intersect with their work at Adaptive. Kathy Thompson (Key Account Manager, clonoSEQ sales) is a stage 1 colorectal cancer ...